TP-317 is a Resolvin E1 (RvE1) drug that activates BLT1 — a GPCR expressed on epithelial and immune cells — to restore and maintain tissue and immune homeostasis without immunosuppression.
In a Phase 1a healthy-volunteer study, oral TP-317 was well-tolerated and demonstrated BLT1 target engagement.
A 12-week study in moderate-to-severe ulcerative colitis patients is scheduled to begin in the second half of 2026.
